Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 264 Carcinoma, Non-Small-Cell Lung 219 Neoplasms 218 Leukemia, Myeloid, Acute 193 Multiple Myeloma 178 Colorectal Neoplasms 175 Melanoma 165 Prostatic Neoplasms 163 Lymphoma 145 Leukemia 142 Lymphoma, Non-Hodgkin 133 Glioblastoma 131 Pancreatic Neoplasms 127 Neoplasm Metastasis 118 Lung Neoplasms 118 Leukemia, Lymphocytic, Chronic, B-Cell 118 Ovarian Neoplasms 112 Precursor Cell Lymphoblastic Leukemia-Lymphoma 106 Recurrence 97 Myelodysplastic Syndromes 93 Hodgkin Disease 92 Lymphoma, Large B-Cell, Diffuse 89 Lymphoma, Follicular 89 Lymphoma, Mantle-Cell 83 Head and Neck Neoplasms 79 Carcinoma, Renal Cell 79 Brain Neoplasms 77 Sarcoma 73 Carcinoma, Hepatocellular 73 Squamous Cell Carcinoma of Head and Neck 71

Interventions

relatlimab 1 daratumumab 1 Nivolumab 1 Ipilimumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Completed × Various Advanced Cancer × Clear all

NCT02488759 2023-11-13

CheckMate358

Bristol-Myers Squibb

Phase 1/2 Completed

578 enrolled 19 charts

Various Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡